OP Asset Management Ltd Invests $680,000 in Arrowhead Pharmaceuticals, Inc. $ARWR

OP Asset Management Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,842 shares of the biotechnology company’s stock, valued at approximately $680,000.

Other hedge funds also recently made changes to their positions in the company. CWM LLC grew its position in Arrowhead Pharmaceuticals by 1.4% in the fourth quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock worth $820,000 after acquiring an additional 168 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Arrowhead Pharmaceuticals by 1.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after purchasing an additional 178 shares in the last quarter. HighTower Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 0.3% during the fourth quarter. HighTower Advisors LLC now owns 133,229 shares of the biotechnology company’s stock worth $8,845,000 after purchasing an additional 340 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in Arrowhead Pharmaceuticals by 1.8% during the fourth quarter. Maryland State Retirement & Pension System now owns 20,241 shares of the biotechnology company’s stock worth $1,344,000 after purchasing an additional 365 shares during the last quarter. Finally, Tsfg LLC bought a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. 62.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

ARWR has been the topic of several recent research reports. Chardan Capital reiterated a “buy” rating and set a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. initiated coverage on Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They issued an “overweight” rating and a $88.00 target price for the company. Leerink Partners upped their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research note on Wednesday, June 17th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $87.27.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $81.51 on Wednesday. The company has a 50-day simple moving average of $76.09 and a two-hundred day simple moving average of $68.51. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $14.30 and a 12-month high of $84.55. The firm has a market cap of $11.48 billion, a price-to-earnings ratio of -37.91 and a beta of 1.28. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million for the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company’s quarterly revenue was down 86.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.75 earnings per share. On average, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. The trade was a 5.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider owned 226,958 shares of the company’s stock, valued at $17,021,850. The trade was a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,065 shares of company stock worth $1,912,662 in the last ninety days. 3.60% of the stock is owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.